[Featured Stock] DSC Inbe, Koimun Blood Cancer Complete Remission... Investment History Highlights 'Strong Performance'

[Asia Economy Reporter Minwoo Lee] DSC Investment's stock price is showing strength. The news that SCM Lifescience and Koimmune, a U.S. affiliate of Genexine, achieved favorable results in clinical trials for a blood cancer treatment has brought attention to past investment records.

As of 10:35 a.m. on the 14th, DSC Investment's stock price rose 4.22% from the previous day to 5,930 KRW. It appears that the positive factor was SCM Lifescience's announcement that Koimmune participated in the American Society of Hematology (ASH) conference and presented clinical results of the company's allogeneic 'CARCIK' technology-based blood cancer treatment targeting patients with B-cell acute lymphoblastic leukemia.

Koimmune administered the 'CARCIK-CD19' cell therapy to a total of 21 patients (4 children, 17 adults), resulting in complete remission in 13 patients (61.9%). Among 15 patients who received two high doses of cells, complete remission was confirmed in 11 patients (73.3%). Most patients showed an increase in CARCIK-CD19 cells, which were measured for up to 22 months.

The CARCIK-CD19 cell therapy, which uses a non-viral method, is expected to be relatively less expensive compared to 'CAR-T' therapies that use viral vectors, as it simplifies virus production costs and designs the process to be less complex. Based on these results, Koimmune aims to list on NASDAQ in the second half of next year.

Meanwhile, DSC Investment executed a $4 million (approximately 4.5 billion KRW) Series A investment in Koimmune last November.